What is the dosage of Augtyro?

Augtyro is available in 1 dosages, including 40 mg Cap

What is Augtyro mechanism of action?

Augtyro mechanism of action is Cytochrome P450 3A4 Inducers, Proto-Oncogene Tyrosine-Protein Kinase ROS1 Inhibitors, Tropomyosin Receptor Tyrosine Kinase A Inhibitors, Tropomyosin Receptor Tyrosine Kinase B Inhibitors or Tropomyosin Receptor Tyrosine Kinase C Inhibitors

Last Update: Oct, 17 2024

Augtyro(repotrectinib)

AUGTYRO 40 MG Oral Capsule

NO BOXED WARNING

Dosage & Administration

* Select patients for the treatment of locally advanced or metastatic NSCLC based on the presence of ROS1 rearrangement(s) in tumor specimens.
* Select patients for treatment of locally advanced or metastatic solid tumors based on the presence of an NTRK gene fusion.
* Recommended Dosage: 160 mg orally once daily for 14 days, then increase to 160 mg twice daily, with or without food.

Get Your Patient on Augtyro

See your patient's specific prior authorization requirements including coverage restrictions and step therapies

Or select your Insurance from the list below:

Augtyro Prescribing Information

Contact Medical Science Liaison

Report Adverse Event

Augtyro Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Sep 24, 2024Arizona - Uniform Prior Authorization Form

Verified: Sep 24, 2024Colorado - Uniform Prior Authorization Form

Verified: Sep 24, 2024Hawaii - Uniform Prior Authorization Form

Verified: Sep 24, 2024Illinois - Uniform Prior Authorization Form

Verified: Sep 24, 2024Indiana - Uniform Prior Authorization Form

Verified: Sep 24, 2024Louisiana - Uniform Prior Authorization Form

Verified: Sep 24, 2024Minnesota - Uniform Prior Authorization Form

Verified: Sep 24, 2024New Hampshire - Uniform Prior Authorization Form

Verified: Sep 24, 2024New Mexico - Uniform Prior Authorization Form

Verified: Sep 24, 2024Oregon - Uniform Prior Authorization Form

Verified: Sep 24, 2024Texas - Uniform Prior Authorization Form

Verified: Oct 05, 2024Washington - Uniform Prior Authorization Form

Verified: Oct 05, 2024Wisconsin - Uniform Prior Authorization Form

BMS Oncology & Reimbursement Form - Spanish

BMS Oncology Access & Reimbursement Form

Benefits investigation

BMS Oncology & Reimbursement Form - Spanish

BMS Oncology Access & Reimbursement Form

Financial Assistance

Financial Assistance Programs

Q: What is Augtyro made of?

Augtyro contains repotrectinib which is a Kinase Inhibitor

Q: How is Augtyro administered?

Augtyro is administered as a Oral Pill

Augtyro retails for $6,747 per dose without insurance or financial assistance.Depending on your patient's insurance situation and other eligibility criteria, they may be able to get Augtyro for significantly less. Review the program information below to determine what program can offer your patient the most benefits.

Copay Card Program$0 Copay

Available for

commercial

Program Details